Item 2.02. Results of Operations and Financial Condition.

On January 5, 2023, Arbutus Biopharma Corporation (the "Company") issued a press release (the "Press Release") announcing its 2023 corporate objectives and provided certain estimated and projected financial information, including its estimated cash, cash equivalents and investments as of December 31, 2022. The amounts included in the Press Release are preliminary, have not been audited and are subject to change upon completion of the Company's audited financial statements for the year ended December 31, 2022. Additional information and disclosures would be required for a more complete understanding of the Company's financial position and results of operations as of December 31, 2022. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated by reference herein.

On January 5, 2023, the Company posted an updated corporate presentation on its website at www.arbutusbio.com (the "Corporate Presentation"), which included the Company's estimated cash, cash equivalents and investments as of December 31, 2022. A copy of the Corporate Presentation is filed herewith as Exhibit 99.2 and is incorporated by reference herein.

Item 8.01. Other Events.

On January 5, 2023, the Company issued the Press Release, a copy of which is filed herewith as Exhibit 99.1 hereto and is incorporated by reference herein.

A copy of the Corporate Presentation is filed herewith as Exhibit 99.2 hereto and is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits.

Exhibit Number       Description

  99.1                 Press release dated January 5, 2023
  99.2                 Corporate Presentation January 5, 2023
104                  Cover Page Interactive Data File (embedded within the
                     Inline XBRL document)

© Edgar Online, source Glimpses